SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK - News) announced that it has initiated two new clinical trials of TLK286 in patients with ovarian cancer. One of the trials will evaluate the combination of TLK286 with Doxil® in patients who have failed platinum-based chemotherapy. The second trial will evaluate TLK286 in combination with carboplatin in patients who have recurrent, platinum- sensitive ovarian cancer.
Doxil® is currently approved for the second-line treatment of advanced ovarian cancer, and is also used for the treatment of breast cancer. Carboplatin is approved for both first-line and reinduction therapy of ovarian cancer, and is also used in the first-line treatment of non-small cell lung cancer.
Recently reported data demonstrate that combinations of TLK286 and Doxil® and TLK286 and carboplatin were synergistic in killing human cancer cells in preclinical testing. These data, combined with the novel mechanism of action of TLK286 and the lack of overlapping toxicities, support the further testing of combination regimens.
"We are pleased to advance the development of TLK286 to treat less- advanced cancer patients with new combination chemotherapy regimens," said Gail L. Brown, M.D., senior vice president and chief medical officer. "Since Doxil® and carboplatin are frequently used to treat other solid tumors, the results of these trials will contribute to our understanding of the potential effectiveness of TLK286 combination regimens in other cancer indications." Telik is also conducting a clinical trial of TLK286 and Taxotere® in non- small cell lung cancer, as well as single agent trials of TLK286 administered weekly in breast, ovarian and non-small cell lung cancer.
TLK286 is a small molecule antitumor drug that has a novel mechanism of action. TLK286 is activated by GST P1-1, an enzyme that is present in higher levels in many human cancers than in normal tissues. Upon activation, TLK286 initiates an intracellular process known as apoptosis, or programmed cell death.
Telik, Inc. of South San Francisco, CA is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs to treat serious diseases for which there is significant demand for new therapies. The company's most advanced drug development candidate is TLK286, a tumor activated small molecule drug that is in Phase 2 clinical trials in ovarian, non-small cell lung, colorectal and breast cancer. Telik's product candidates were discovered using its proprietary technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com . |
